基于导管的内血管胆固醇和肝硬化为2型糖尿病:一个多中心,开放标签,单臂研究
Zhi Wang1, Tao Pan1, Weifu Lv2
1Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Signal transduction and targeted therapy
|November 13, 2025
概括
血管内 (EDN) 在2型糖尿病 (T2D) 患者中安全改善了血糖控制. 这种针对交感性过活性的程序显著降低了HbA1c水平并改善了葡萄糖控制,这需要进一步的研究.
科学领域:
- 内分泌学和新陈代谢学
- 心血管干预 心血管干预
- 糖尿病研究研究 糖尿病研究
背景情况:
- 交感神经系统的过度活跃是2型糖尿病 (T2D) 中高血糖的关键驱动因素.
- 现有的治疗方法往往无法在T2D患者中实现最佳的血糖控制.
- 针对异常的同情信号,为T2D管理提供了潜在的治疗途径.
研究的目的:
- 评估内血管缩 (EDN) 的安全性和有效性,用于控制不良的T2D患者.
- 评估EDN对糖化血红蛋白 (HbA1c) 和其他血糖参数的影响.
- 调查程序安全,包括重大不良事件 (MAE).
主要方法:
- 一个多中心,开放标签,单臂试验,涉及30名T2D患者,HbA1c>7.5%,尽管标准治疗.
- 针对乳房动脉和肝动脉的EDN程序.
- 1,3,6和12个月的后续评估,监测HbA1c,禁食血葡萄糖和不良事件.
主要成果:
- 在手术后30天内,没有观察到与设备或手术相关的重大不良事件 (MAE).
- 6个月后平均HbA1c显著减少1.0% (P < 0.001),在12个月后持续减少.
- 增加时间范围 (3.9-10.0 mmol/L) 和观察到血压的降低.
结论:
- 血管内膜消毒 (EDN) 似乎是一种安全有效的辅助疗法,用于改善T2D的血糖控制.
- 该程序显示HbA1c显著降低,并改善了葡萄糖的可变性.
- 这些探索性发现支持通过随机对照试验进一步调查,以确认EDN在T2D管理中的有效性.
更多相关视频
04:09Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
3.6K
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
664
相关概念视频
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...